Show simple item record

dc.contributor.authorSingh, Rekha
dc.contributor.authorRothman, Alan L.
dc.contributor.authorPotts, James A.
dc.contributor.authorGuirakhoo, Farshad
dc.contributor.authorEnnis, Francis A.
dc.contributor.authorGreen, Sharone
dc.date2022-08-11T08:09:09.000
dc.date.accessioned2022-08-23T16:19:21Z
dc.date.available2022-08-23T16:19:21Z
dc.date.issued2010-07-15
dc.date.submitted2017-08-04
dc.identifier.citationJ Infect Dis. 2010 Jul 15;202(2):223-33. doi: 10.1086/653486. <a href="https://doi.org/10.1086/653486">Link to article on publisher's site</a>
dc.identifier.issn0022-1899 (Linking)
dc.identifier.doi10.1086/653486
dc.identifier.pmid20536361
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35025
dc.description.abstractFlavivirus vaccines based on ChimeriVax technology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope genes of heterologous flaviviruses, such as Japanese encephalitis and West Nile viruses. These chimeric vaccines induce both humoral and cell-mediated immunity. Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/JE), or chimeric West Nile virus (YF/WN) vaccines, followed by a secondary homologous or heterologous vaccination; the hierarchy and function of CD8(+) T cell responses to a variable envelope epitope were then analyzed and compared with those directed against a conserved immunodominant yellow fever virus NS3 epitope. Sequential vaccination with heterologous chimeric flaviviruses generated a broadly cross-reactive CD8(+) T cell response dependent on both the sequence of infecting viruses and epitope variant. The enhanced responses to variant epitopes after heterologous vaccination were not related to preexisting antibody or to higher virus titers. These results demonstrate that the sequence of vaccination affects the expansion of cross-reactive CD8(+) T cells after heterologous chimeric flavivirus challenge.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20536361&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903744/
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.titleSequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses
dc.typeJournal Article
dc.source.journaltitleThe Journal of infectious diseases
dc.source.volume202
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/241
dc.identifier.contextkey10542756
html.description.abstract<p>Flavivirus vaccines based on ChimeriVax technology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope genes of heterologous flaviviruses, such as Japanese encephalitis and West Nile viruses. These chimeric vaccines induce both humoral and cell-mediated immunity. Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/JE), or chimeric West Nile virus (YF/WN) vaccines, followed by a secondary homologous or heterologous vaccination; the hierarchy and function of CD8(+) T cell responses to a variable envelope epitope were then analyzed and compared with those directed against a conserved immunodominant yellow fever virus NS3 epitope. Sequential vaccination with heterologous chimeric flaviviruses generated a broadly cross-reactive CD8(+) T cell response dependent on both the sequence of infecting viruses and epitope variant. The enhanced responses to variant epitopes after heterologous vaccination were not related to preexisting antibody or to higher virus titers. These results demonstrate that the sequence of vaccination affects the expansion of cross-reactive CD8(+) T cells after heterologous chimeric flavivirus challenge.</p>
dc.identifier.submissionpathinfdis_pp/241
dc.contributor.departmentDivision of Infectious Diseases and Immunology, Department of Medicine
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages223-33


This item appears in the following Collection(s)

Show simple item record